Cerebral Amyloid AngiopathyHIFI-CAANCT06128824
High Frequency Imaging in Cerebral Amyloid Angiopathy
An observational study of Cerebral Amyloid Angiopathy, run by Martin Dichgans at 3 sites in Germany.
Trial summary
Cerebral amyloid angiopathy (CAA), caused by amyloid beta depositions in the walls of small cerebral vessels, is remarkably common in the elderly. Its major clinical consequences include intracerebral hemorrhages (ICH) typically in lobar location, functional dependence (disability) and cognitive impairment. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Cerebral Amyloid Angiopathy
- What is being tested?
- MR Imaging
- How many people
- 75 participants
- Where
- 3 sitesGermany
- Study dates
- 19 Mar 2019to 31 May 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study will be performed in a hospital-based setting. Patients with probable CAA according to the modified Boston criteria or Boston criteria v2.0 will be further evaluated for study participation.
Who may be able to join
- Probable CAA according to the modified Boston criteria with evidence of
- cSS or fSAH
- lobar ICH survivors without cSS or fSAH
- Absence of ICH or microbleed in deep locations (basal ganglia, thalamus, brain stem)
- Absence of infratentorial siderosis or infratentorial SAH
- MR-/CT-/DS-angiography without evidence of cerebral aneurysm, AVM, AV-fistula or other possible etiology for the observed haemorrhagic manifestations
- No history of head trauma resulting in loss of consciousness or radiologically visible traumatic brain injury
- Written informed consent by patient herself/himself prior to study enrolment
Who cannot join
- Unwillingness to participate in high-frequency (monthly) follow-up
- Severe medical condition with expected life expectancy <1 year
- Contraindications for MRI (following local guidelines of the respective study center)
Trial locations and contacts
3 sites in 1 country.
Germany3 sites
DZNE/Bonn - Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn
Bonn
DZNE/Magdeburg - Universitätsklinikum Magdeburg
Magdeburg
Insitute for Stroke and Dementia Research
Munich, 81377
About this study
Official title: High Frequency Imaging in Patients With Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy (CAA), caused by amyloid beta depositions in the walls of small cerebral vessels, is remarkably common in the elderly. Its major clinical consequences include intracerebral hemorrhages (ICH) typically in lobar location, functional dependence (disability) and cognitive impairment.
Cortical superficial siderosis (cSS) is a common finding in CAA patients and can even be the only magnetic resonance imaging sign of CAA. cSS is of high prognostic relevance regarding future intracerebral haemorrhage and disability. Previous studies suggest that cSS is caused by recurrent focal subarachnoid hemorrhages (fSAH). However, the exact mechanisms and the temporal dynamics of this highly relevant imaging finding are largely unknown.
Read more
In addition to hemorrhagic manifestations, such as cSS, CAA patients also show ischemic lesions. Of particular interest are acute ischemic lesions as detected by diffusion imaging, which seem to be highly prevalent. Since haemorrhagic and ischemic lesions require fundamentally different therapeutic strategies, understanding the relevance and interplay of both lesion types is highly important for clinical decision making.
The HIFI-CAA cohort study aims to provide novel insights into cSS, acute ischemic lesions and other relevant brain alterations in CAA through high-frequency (monthly) serial magnetic resonance imaging.
Read the detailed description
Cerebral amyloid angiopathy (CAA) is defined as the deposition of β-amyloid in the walls of small cortical cerebral vessels. It is very common in the elderly population with prevalence rates up to 60% and is associated with Alzheimer´s disease. Intracerebral lobar macrohemorrhages (ICH) are the most devastating presentation of CAA and the main cause of morbidity and mortality. In addition to developing clinically manifest strokes, CAA patients may also suffer from transient neurological symptoms and progressive cognitive impairment ultimately resulting in dementia.
Apart from ICH, typical MRI signs of CAA include multiple cerebral microbleeds (CMB) in a cortical-subcortical localization, white matter hyperintensities on T2-weighted images and supratentorial cortical superficial siderosis (cSS). Main risk factors for recurrence of CAA-related ICH are apolipoprotein E ε2 or ε4 alleles, previous ICHs and CMB on follow-up imaging. Recently, cSS emerged as an additional, major independent risk factor for ICH and disability.
In CAA, siderosis affects the convexity of the cerebral hemispheres, and thus is termed cortical superficial siderosis (cSS). This is in contrast to infratentorial superficial siderosis, which is not linked to CAA. CSS is likely caused by recurrent non-traumatic, focal convexity subarachnoid hemorrhages (fSAH). There are causes of fSAH and cSS other than CAA, and these causes seem to vary depending on age: in younger patients (< 60 years of age) fSAH and cSS are most commonly seen in the context of trauma, vasculitis and reversible cerebral vasoconstriction syndrome, while CAA seems to be the by far most common cause in subjects above 60 years of age. cSS is common (> 60%) in patients with histologically proven CAA, and may be the only hemorrhagic imaging sign on MRI.
Lesions on diffusion-weighted imaging, i.e. areas of restricted diffusion, are a very frequent finding in CAA. These diffusion restrictions can be found in 25% to 50% of CAA patients when performing a single MRI. One recent study even suggests a spatial relationship with cSS. The clinical significance of these lesions is not yet fully established. The most likely pathophysiology behind these lesions is acute ischemia, or to be more precise cytotoxic edema after brain ischemia/infarction. However, subcortical infarcts as detected through a diffusion-restricted lesion can have vastly different fates, ranging from disappearance to complete brain tissue loss (cavitation). An important step in the understanding of these lesions is the precise estimation of prevalence and tissue consequences. A critical point in this endeavour is that these diffusion restricted lesions are typically only visible for a few weeks. Thus, they can remain completely undetected in studies using conventional study designs with follow-up intervals as long as 6 months, one year or even longer.
While small subcortical and cortical ischemic lesions (detectable as diffusion restrictions) are a common finding in CAA patients, their exact prevalence and relevance for disease progression are unclear. Overall, temporal dynamics of the processes leading to hemorrhagic and ischemic manifestations of CAA as well as their interrelationships are insufficiently understood. These critical aspects can be addressed by a novel study design with serial, monthly magnetic resonance imaging. The study design is inspired by a recent high-frequency serial imaging study in patients with sporadic, non-amyloid cerebral small vessel disease conducted at Nijmegen (Radboud University Nijmegen Diffusion tensor and Magnetic resonance imaging Cohort - Investigating The origin and Evolution of cerebral small vessel disease, RUN DMC - InTENse).
The primary aim of this study is to prospectively evaluate the development and temporal evolution of incident and prevalent fSAH \& cSS in CAA patients.
Secondary aims are i) to assess the monthly incidence of acute ischemic lesions (diffusion restrictions) in CAA patients with cSS/fSAH and to compare the incidence with lobar ICH survivors, and ii) to assess the inter-relationship between hemorrhagic lesions (fSAH/cSS/CMB) and acute ischemic lesions as well as the association between these lesions and cerebrovascular event rates and functional status.
- Conditions
- Cerebral Amyloid Angiopathy
- Being tested
- MR Imaging
- Keywords
- cortical superficial siderosis, DWI+ lesion, serial imaging, disease progression, MRI, cerebrovascular events, focal subarachnoid hemorrhage
- Medical subject headings
- Cerebral Amyloid Angiopathy, Disease Progression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MR ImagingOther
Serial magnetic resonance imaging (MRI)
| Study group | Role | What they receive |
|---|---|---|
| Patients with probable CAA and cSS or fSAH | Patients with probable CAA and cortical superficial siderosis (cSS) or focal subarachnoid haemorrhage (fSAH) Receives: Other: MR Imaging | |
| Patients with probable CAA without cSS or fSAH | Patients with probable CAA and intracerebral hemorrhage (ICH; micro- or macrohemorrhage) but without cSS or fSAH Receives: Other: MR Imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
new hemorrhagic features as determined by heme-sensitive MRI
new hemorrhagic features (e.g., cSS) as determined by heme-sensitive magnetic resonance imaging such as T2*-weighted gradient echo (GRE) and susceptibility weighted imaging (SWI)
Measured: monthly up to 12 months
Secondary outcomes (6)
DWI+ lesions on diffusion weighted imaging MRI
DWI+ lesions on diffusion weighted imaging (DWI) on magnetic resonance imaging
Measured: monthly up to 12 months
modified Rankin Scale
functional outcome on modified Rankin Scale (score [0-6] with higher scores meaning a worse outcome)
Measured: monthly up to 12 months
neuropsychological evaluation (global cognition using MoCA)
neuropsychological evaluation of cognition using the Montreal Cognitive Assessment (MoCA) (score [0-30] with higher scores meaning a better outcome)
Measured: baseline and after 12 months
neuropsychological evaluation (global cognition using MMSE)
neuropsychological evaluation of cognition using the Mini Mental State Examination (MMSE) (score [0-30] with higher scores meaning a better outcome)
Measured: baseline and after 12 months
neuropsychological evaluation (processing speed and executive function)
neuropsychological evaluation of processing speed and executive function using the Trail Making Test (TMT) A and TMT B measuring the time in seconds to complete the task; age- and education-corrected z-scores will be derived
Measured: baseline and after 12 months
reaction time (attention)
reaction time assessed with Test of Attentional Performance (TAP) test
Measured: monthly up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Nov 2023
- Study start19 Mar 2019
- Primary completion31 May 2026 (estimated)
- Study completion31 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cerebral Amyloid AngiopathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Martin Dichgans
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Martin Dichgans, Ludwig-Maximilians - University of Munich
- Investigators
- Marco Duering, MD, Principal investigator, Institute for Stroke and Dementia Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06128824
- Sponsor's protocol ID
- HIFI-CAA-01
- Acronym
- HIFI-CAA
- Status last verified
- Sep 2025
- First submitted
- 26 Oct 2023
- Last updated
- 12 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: has to be further decided, upon reasonable request
Study at a glance
From the registry record, last updated by the sponsor on 12 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- High Frequency Imaging in Patients With Cerebral Amyloid Angiopathy
- ClinicalTrials.gov ID
- NCT06128824
- Acronym / sponsor ID
- HIFI-CAA / HIFI-CAA-01
- Conditions
- Cerebral Amyloid Angiopathy
- Keywords
- cortical superficial siderosis, DWI+ lesion, serial imaging, disease progression, MRI, cerebrovascular events, focal subarachnoid hemorrhage
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- Martin DichgansUniversity, hospital or other
- Study start
- 19 Mar 2019 (actual)
- Primary completion
- 31 May 2026 (estimated)
- Study completion
- 31 May 2026 (estimated)
- First posted
- 13 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cerebral amyloid angiopathy (CAA), caused by amyloid beta depositions in the walls of small cerebral vessels, is remarkably common in the elderly. Its major clinical consequences include intracerebral hemorrhages (ICH) typically in lobar location, functional dependence (disability) and cognitive impairment.
Cortical superficial siderosis (cSS) is a common finding in CAA patients and can even be the only magnetic resonance imaging sign of CAA. cSS is of high prognostic relevance regarding future intracerebral haemorrhage and disability. Previous studies suggest that cSS is caused by recurrent focal subarachnoid hemorrhages (fSAH). However, the exact mechanisms and the temporal dynamics of this highly relevant imaging finding are largely unknown.
In addition to hemorrhagic manifestations, such as cSS, CAA patients also show ischemic lesions. Of particular interest are acute ischemic lesions as detected by diffusion imaging, which seem to be highly prevalent. Since haemorrhagic and ischemic lesions require fundamentally different therapeutic strategies, understanding the relevance and interplay of both lesion types is highly important for clinical decision making.
The HIFI-CAA cohort study aims to provide novel insights into cSS, acute ischemic lesions and other relevant brain alterations in CAA through high-frequency (monthly) serial magnetic resonance imaging.
Detailed description
Cerebral amyloid angiopathy (CAA) is defined as the deposition of β-amyloid in the walls of small cortical cerebral vessels. It is very common in the elderly population with prevalence rates up to 60% and is associated with Alzheimer´s disease. Intracerebral lobar macrohemorrhages (ICH) are the most devastating presentation of CAA and the main cause of morbidity and mortality. In addition to developing clinically manifest strokes, CAA patients may also suffer from transient neurological symptoms and progressive cognitive impairment ultimately resulting in dementia.
Apart from ICH, typical MRI signs of CAA include multiple cerebral microbleeds (CMB) in a cortical-subcortical localization, white matter hyperintensities on T2-weighted images and supratentorial cortical superficial siderosis (cSS). Main risk factors for recurrence of CAA-related ICH are apolipoprotein E ε2 or ε4 alleles, previous ICHs and CMB on follow-up imaging. Recently, cSS emerged as an additional, major independent risk factor for ICH and disability.
In CAA, siderosis affects the convexity of the cerebral hemispheres, and thus is termed cortical superficial siderosis (cSS). This is in contrast to infratentorial superficial siderosis, which is not linked to CAA. CSS is likely caused by recurrent non-traumatic, focal convexity subarachnoid hemorrhages (fSAH). There are causes of fSAH and cSS other than CAA, and these causes seem to vary depending on age: in younger patients (< 60 years of age) fSAH and cSS are most commonly seen in the context of trauma, vasculitis and reversible cerebral vasoconstriction syndrome, while CAA seems to be the by far most common cause in subjects above 60 years of age. cSS is common (> 60%) in patients with histologically proven CAA, and may be the only hemorrhagic imaging sign on MRI.
Lesions on diffusion-weighted imaging, i.e. areas of restricted diffusion, are a very frequent finding in CAA. These diffusion restrictions can be found in 25% to 50% of CAA patients when performing a single MRI. One recent study even suggests a spatial relationship with cSS. The clinical significance of these lesions is not yet fully established. The most likely pathophysiology behind these lesions is acute ischemia, or to be more precise cytotoxic edema after brain ischemia/infarction. However, subcortical infarcts as detected through a diffusion-restricted lesion can have vastly different fates, ranging from disappearance to complete brain tissue loss (cavitation). An important step in the understanding of these lesions is the precise estimation of prevalence and tissue consequences. A critical point in this endeavour is that these diffusion restricted lesions are typically only visible for a few weeks. Thus, they can remain completely undetected in studies using conventional study designs with follow-up intervals as long as 6 months, one year or even longer.
While small subcortical and cortical ischemic lesions (detectable as diffusion restrictions) are a common finding in CAA patients, their exact prevalence and relevance for disease progression are unclear. Overall, temporal dynamics of the processes leading to hemorrhagic and ischemic manifestations of CAA as well as their interrelationships are insufficiently understood. These critical aspects can be addressed by a novel study design with serial, monthly magnetic resonance imaging. The study design is inspired by a recent high-frequency serial imaging study in patients with sporadic, non-amyloid cerebral small vessel disease conducted at Nijmegen (Radboud University Nijmegen Diffusion tensor and Magnetic resonance imaging Cohort - Investigating The origin and Evolution of cerebral small vessel disease, RUN DMC - InTENse).
The primary aim of this study is to prospectively evaluate the development and temporal evolution of incident and prevalent fSAH \& cSS in CAA patients.
Secondary aims are i) to assess the monthly incidence of acute ischemic lesions (diffusion restrictions) in CAA patients with cSS/fSAH and to compare the incidence with lobar ICH survivors, and ii) to assess the inter-relationship between hemorrhagic lesions (fSAH/cSS/CMB) and acute ischemic lesions as well as the association between these lesions and cerebrovascular event rates and functional status.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with probable CAA and cSS or fSAH | – | Other: MR ImagingPatients with probable CAA and cortical superficial siderosis (cSS) or focal subarachnoid haemorrhage (fSAH) |
| Patients with probable CAA without cSS or fSAH | – | Other: MR ImagingPatients with probable CAA and intracerebral hemorrhage (ICH; micro- or macrohemorrhage) but without cSS or fSAH |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study will be performed in a hospital-based setting. Patients with probable CAA according to the modified Boston criteria or Boston criteria v2.0 will be further evaluated for study participation.
Key inclusion criteria (8 listed)
- Probable CAA according to the modified Boston criteria with evidence of
- Absence of ICH or microbleed in deep locations (basal ganglia, thalamus, brain stem)
- Absence of infratentorial siderosis or infratentorial SAH
- MR-/CT-/DS-angiography without evidence of cerebral aneurysm, AVM, AV-fistula or other possible etiology for the observed haemorrhagic manifestations
- No history of head trauma resulting in loss of consciousness or radiologically visible traumatic brain injury
Key exclusion criteria (3 listed)
- Unwillingness to participate in high-frequency (monthly) follow-up
- Severe medical condition with expected life expectancy <1 year
- Contraindications for MRI (following local guidelines of the respective study center)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MR ImagingSerial magnetic resonance imaging (MRI) | Other | Patients with probable CAA and cSS or fSAH, Patients with probable CAA without cSS or fSAH |
Primary outcome
new hemorrhagic features as determined by heme-sensitive MRI
Time frame: monthly up to 12 months
new hemorrhagic features (e.g., cSS) as determined by heme-sensitive magnetic resonance imaging such as T2*-weighted gradient echo (GRE) and susceptibility weighted imaging (SWI)
6 secondary outcomes
DWI+ lesions on diffusion weighted imaging MRI
Time frame: monthly up to 12 months
modified Rankin Scale
Time frame: monthly up to 12 months
neuropsychological evaluation (global cognition using MoCA)
Time frame: baseline and after 12 months
neuropsychological evaluation (global cognition using MMSE)
Time frame: baseline and after 12 months
neuropsychological evaluation (processing speed and executive function)
Time frame: baseline and after 12 months
reaction time (attention)
Time frame: monthly up to 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Sep 2025.
- Individual participant dataSharing planned: Undecided. has to be further decided, upon reasonable request
Related trials for Cerebral Amyloid Angiopathy
Active, not recruitingPhase 2
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
RecruitingPhase 3
Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
RecruitingObservational study
Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.
Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
Recruiting
Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)
Stroke, Moyamoya Disease
Active, not recruitingPhase 2
Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marco Duering, MD principal investigator
Institute for Stroke and Dementia Research
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cerebral Amyloid Angiopathy, run by Martin Dichgans at 3 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 12 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
new hemorrhagic features as determined by heme-sensitive MRI (time frame: monthly up to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2025.